Active Cancer NIHR-supported project Infection & Immunity
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy (ACT-HOV-AML-002 (EVOLVE 2)/ HOVON 177)
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Gerardo Errico (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapyEVOLVE 2 : A Joint Study of HOVON, AMLSG and UKAMLRN
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
A Phase II, Randomised, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Venetoclax and Azacitidine versus Intensive Chemotherapy in Fit Adults with High Risk Newly Diagnosed Acute Myeloid Leukaemia (ACT-AML-001)
A Phase II, Randomised, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in CombiN/Ation with Venetoclax and Azacitidine versus Intensive Chemotherapy in Fit Adults with High Risk Newly Diagnosed Acute Myeloid Leukaemia (ACT-AML-001)
A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know